140 related articles for article (PubMed ID: 17550887)
1. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1.
Biswas S; Smith C; Field HJ
J Antimicrob Chemother; 2007 Aug; 60(2):274-9. PubMed ID: 17550887
[TBL] [Abstract][Full Text] [Related]
2. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
[TBL] [Abstract][Full Text] [Related]
3. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
Biswas S; Jennens L; Field HJ
Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
[TBL] [Abstract][Full Text] [Related]
4. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.
Liuzzi M; Kibler P; Bousquet C; Harji F; Bolger G; Garneau M; Lapeyre N; McCollum RS; Faucher AM; Simoneau B; Cordingley MG
Antiviral Res; 2004 Dec; 64(3):161-70. PubMed ID: 15550269
[TBL] [Abstract][Full Text] [Related]
6. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant.
Sukla S; Biswas S; Birkmann A; Lischka P; Ruebsamen-Schaeff H; Zimmermann H; Field HJ
Antiviral Res; 2010 Jul; 87(1):67-73. PubMed ID: 20420855
[TBL] [Abstract][Full Text] [Related]
7. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
Biswas S; Swift M; Field HJ
Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
[TBL] [Abstract][Full Text] [Related]
8. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
9. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
10. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir.
Field HJ; Huang ML; Lay EM; Mickleburgh I; Zimmermann H; Birkmann A
Antiviral Res; 2013 Nov; 100(2):297-9. PubMed ID: 24021190
[TBL] [Abstract][Full Text] [Related]
11. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome.
Ziyaeyan M; Alborzi A; Japoni A; Kadivar M; Davarpanah MA; Pourabbas B; Abassian A
Int J Dermatol; 2007 Dec; 46(12):1263-6. PubMed ID: 18173520
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
[TBL] [Abstract][Full Text] [Related]
13. Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor.
Sukla S; Biswas S; Birkmann A; Lischka P; Zimmermann H; Field HJ
J Antimicrob Chemother; 2010 Jul; 65(7):1347-52. PubMed ID: 20453068
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.
Spector FC; Liang L; Giordano H; Sivaraja M; Peterson MG
J Virol; 1998 Sep; 72(9):6979-87. PubMed ID: 9696789
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
Saijo M; Yasuda Y; Yabe H; Kato S; Suzutani T; De Clercq E; Niikura M; Maeda A; Kurane I; Morikawa S
J Med Virol; 2002 Sep; 68(1):99-104. PubMed ID: 12210436
[TBL] [Abstract][Full Text] [Related]
16. Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients.
Stránská R; van Loon AM; Polman M; Beersma MF; Bredius RG; Lankester AC; Meijer E; Schuurman R
Antivir Ther; 2004 Aug; 9(4):565-75. PubMed ID: 15456088
[TBL] [Abstract][Full Text] [Related]
17. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
Kleymann G; Fischer R; Betz UA; Hendrix M; Bender W; Schneider U; Handke G; Eckenberg P; Hewlett G; Pevzner V; Baumeister J; Weber O; Henninger K; Keldenich J; Jensen A; Kolb J; Bach U; Popp A; Mäben J; Frappa I; Haebich D; Lockhoff O; Rübsamen-Waigmann H
Nat Med; 2002 Apr; 8(4):392-8. PubMed ID: 11927946
[TBL] [Abstract][Full Text] [Related]
18. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus.
Field HJ; Biswas S
Drug Resist Updat; 2011 Feb; 14(1):45-51. PubMed ID: 21183396
[TBL] [Abstract][Full Text] [Related]
19. Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACV-sensitive and 14 ACV-resistant viruses.
Frobert E; Cortay JC; Ooka T; Najioullah F; Thouvenot D; Lina B; Morfin F
Antiviral Res; 2008 Jul; 79(1):28-36. PubMed ID: 18336925
[TBL] [Abstract][Full Text] [Related]
20. A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure.
Biswas S; Miguel RN; Sukla S; Field HJ
J Gen Virol; 2009 Aug; 90(Pt 8):1937-1942. PubMed ID: 19403757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
